Kinarus Therapeutics (SIX:KNRS): Funding & Investors (Sep 2026)
Kinarus is a biopharmaceutical company that develops differentiated medicines in areas of stress related inflammatory processes based on cross disease area target assessment.
Kinarus Therapeutics (SIX:KNRS) has raised $30.2M across 3 funding rounds on record, the most recent an undisclosed round of $1.7M announced in May 2023.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Kinarus Therapeutics (SIX:KNRS) Company Profile and Key Stats
Latest funding round on record: May 2023.
Kinarus Therapeutics (SIX:KNRS) Funding Rounds
Kinarus Therapeutics (SIX:KNRS) raised $7.6M in a Grant announced in Dec 2021.
8 months later, a Post-IPO Debt of $20.9M was announced in Aug 2022.
9 months later, an undisclosed round of $1.7M was announced in May 2023.
Kinarus Therapeutics (SIX:KNRS) Founders and Leadership Team
Contact details for the Kinarus Therapeutics (SIX:KNRS) team: 1 of 1 has an email address on file.
Start 14-day free trial →Kinarus Therapeutics (SIX:KNRS) Funding Compared to Other Biotechnology Startups
Kinarus Therapeutics (SIX:KNRS)'s latest round of $1.7M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Kinarus Therapeutics (SIX:KNRS) in Biotechnology and Basel
Companies Similar to Kinarus Therapeutics (SIX:KNRS)
Adaptyv Biosystems developing a protein engineering platform using cell-free synthetic biology and…
At Immitra Bio, we are developing a unique genetic medicine platform that combines two of the most powerful…
compliag is providing agile solutions for regulated industries, including the licencing, manufacturing and…
MoonLake Immunotherapeutics is a biopharmaceutical company in the clinical stage that is developing new…
Isospec Analytics SA is a life science company that aims at simplifying molecular identification. We are…
Cria Technologies reinvents cold-chain transport with high-vacuum insulation technology that offers…
Precise Health is a phage therapy platform that specialises in improving and treating bacterial infections to…
AC Immune is a biopharmaceutical company based in Switzerland that is currently in the clinical stage. They…
AlveoliX provides in-vitro solutions based on proprietary and unique organ-on-chip technologies aimed at…
Combioxin SA is clinical-stage biotech company developing innovative anti-virulence drugs to treat severe…
MindMaze is a digital neurotherapeutic platform that provides digital assessments and therapeutics to treat…
Neurosoft Bioelectronics is developing next-generation soft implantable electrodes to interface with the…
Kinarus Therapeutics (SIX:KNRS) Funding FAQs
What does Kinarus Therapeutics (SIX:KNRS) do?
Kinarus is a biopharmaceutical company that develops differentiated medicines in areas of stress related inflammatory processes based on cross disease area target assessment.
How much funding has Kinarus Therapeutics (SIX:KNRS) raised?
Kinarus Therapeutics (SIX:KNRS) has raised $30.2M across 3 rounds on record. The most recent is an undisclosed round of $1.7M announced in May 2023.
When did Kinarus Therapeutics (SIX:KNRS) last raise funding?
Kinarus Therapeutics (SIX:KNRS)'s most recent funding round on record is an undisclosed round of $1.7M, announced in May 2023.
Who is the CEO of Kinarus Therapeutics (SIX:KNRS)?
Alexander Bausch is listed as CEO at Kinarus Therapeutics (SIX:KNRS).
Where is Kinarus Therapeutics (SIX:KNRS) headquartered?
Kinarus Therapeutics (SIX:KNRS) is based in Basel, Basel-Stadt, Switzerland.
How many employees does Kinarus Therapeutics (SIX:KNRS) have?
Kinarus Therapeutics (SIX:KNRS) is in the 11-50 employee band.
How does Kinarus Therapeutics (SIX:KNRS)'s funding compare to other Biotechnology startups?
Kinarus Therapeutics (SIX:KNRS)'s latest round of $1.7M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Kinarus Therapeutics (SIX:KNRS) Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Kinarus Therapeutics (SIX:KNRS) is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.